BETAMETHASONE DIPROPIONATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Betamethasone Dipropionate, and when can generic versions of Betamethasone Dipropionate launch?
Betamethasone Dipropionate is a drug marketed by Anda Repository, Fougera Pharms, Glenmark Generics, Padagis Israel, Taro, Actavis Mid Atlantic, Cosette, Perrigo New York, Pharmaderm, Teva, Zydus Pharms, Encube, Hikma, Alpharma Us Pharms, Fougera Pharms Inc, Padagis Us, Shree Hari Intl, Lupin Ltd, Tasman Pharma, and Zydus Lifesciences. and is included in forty-six NDAs.
The generic ingredient in BETAMETHASONE DIPROPIONATE is betamethasone dipropionate. There are sixty-six drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the betamethasone dipropionate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Betamethasone Dipropionate
A generic version of BETAMETHASONE DIPROPIONATE was approved as betamethasone dipropionate by FOUGERA PHARMS on June 26th, 1984.
Summary for BETAMETHASONE DIPROPIONATE
US Patents: | 0 |
Applicants: | 20 |
NDAs: | 46 |
Finished Product Suppliers / Packagers: | 21 |
Raw Ingredient (Bulk) Api Vendors: | 50 |
Clinical Trials: | 65 |
Patent Applications: | 4,152 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for BETAMETHASONE DIPROPIONATE |
Drug Sales Revenues: | Drug sales revenues for BETAMETHASONE DIPROPIONATE |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for BETAMETHASONE DIPROPIONATE |
What excipients (inactive ingredients) are in BETAMETHASONE DIPROPIONATE? | BETAMETHASONE DIPROPIONATE excipients list |
DailyMed Link: | BETAMETHASONE DIPROPIONATE at DailyMed |
Recent Clinical Trials for BETAMETHASONE DIPROPIONATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Oticara Australia PTY LTD | Phase 2 |
Affiliated Hospital of Nantong University | N/A |
Oticara Australia PTY LTD | Phase 1 |
Pharmacology for BETAMETHASONE DIPROPIONATE
Drug Class | Corticosteroid |
Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for BETAMETHASONE DIPROPIONATE
Paragraph IV (Patent) Challenges for BETAMETHASONE DIPROPIONATE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
SERNIVO | Topical Spray | betamethasone dipropionate | 0.05% | 208079 | 1 | 2018-02-15 |
US Patents and Regulatory Information for BETAMETHASONE DIPROPIONATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pharmaderm | BETAMETHASONE DIPROPIONATE | betamethasone dipropionate | OINTMENT;TOPICAL | 019140-001 | Sep 4, 1984 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Actavis Mid Atlantic | BETAMETHASONE DIPROPIONATE | betamethasone dipropionate | OINTMENT, AUGMENTED;TOPICAL | 074304-001 | Aug 31, 1995 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Zydus Lifesciences | BETAMETHASONE DIPROPIONATE | betamethasone dipropionate | OINTMENT;TOPICAL | 214048-001 | Jul 14, 2020 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Padagis Us | BETAMETHASONE DIPROPIONATE | betamethasone dipropionate | LOTION;TOPICAL | 072538-001 | Jan 31, 1990 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |